BMY Jan 2026 57.500 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

1.9000

-0.0800

(-4.04%)

As of 11:21AM EDT. Market open.

Zacks
A Look at Pharma ETFs Post Q1 Earnings
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
Business Wire
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
PRINCETON, N.J., May 07, 2024--Bristol Myers Squibb to Participate in Upcoming Investor Conferences
Business Wire
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)
PRINCETON, N.J., May 06, 2024--U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)